Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Unadjusted response rates for LDA or remission at 1 year in all patients and by subgroup in the trimmed and stratified-matched populations

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

  Trimmed population Stratified-matched population
Rituximab Anti-TNF agent Rituximab Anti-TNF
(n = 265) (n = 737) (n = 205) (n = 205)
Patients, number LDA or remission Patients, number LDA or remission Patients, number LDA or remission Patients, number LDA or remission
Overall, n (%)* 265 91 (34.3) 737 248 (33.7) 205 75 (36.6) 205 59 (28.8)
 Remained on drug 165 71 (43.0) 379 196 (51.7) 127 59 (46.5) 94 45 (47.9)
 Not retreated with rituximab or discontinued anti-TNF 57 20 (35.1) 141 52 (36.9) 47 16 (34.0) 40 14 (35.0)
 Switched 43 N/A 217 N/A 31 N/A 71 N/A
  1. * P = 0.82 for the trimmed population; P = 0.09 for the stratified-matched population. Anti-TNF anti–tumor necrosis factor, LDA low disease activity, N/A not available